Despite the fact that the results of a retrospective study should be interpreted with caution, it seems that the determination of the KRAS-BRAF mutational status, with additional screening of CRC tumours for their EREG mRNA expression, could help stratify patients likely to benefit from a regimen containing an anti-EGFR moAb. This evidence concerns the gene EGFR and colorectal carcinoma.